A multiplex urinary immunoassay for bladder cancer detection: analysis of a Japanese cohort

Table 3 Individual and combined biomarker performance data for bladder cancer detection

Biomarker	AUC	95 % CI	No of correctly predicted events	No of correctly predicted nonevents	No of nonevents predicted as events	No of events Predicted as nonevents	Sensitivity	Specificity	PPV	NPV
IL8	0.7039	0.6332–0.7746	151	43	24	60	0.716	0.642	0.863	0.417
MMP9	0.6315	0.5541–0.7090	104	51	16	107	0.493	0.761	0.867	0.323
SERPINA1	0.8027	0.7432–0.8622	163	49	18	48	0.773	0.731	0.901	0.505
ANG	0.7835	0.7241–0.8430	155	49	18	56	0.735	0.731	0.896	0.467
VEGFA	0.6488	0.5774–0.7202	89	54	13	122	0.422	0.806	0.873	0.307
CA9	0.7202	0.6550–0.7855	100	59	8	111	0.474	0.881	0.926	0.347
MMP10	0.6214	0.5433–0.6996	175	29	38	36	0.829	0.433	0.822	0.446
APOE	0.6298	0.5614–0.6983	83	63	4	128	0.393	0.940	0.954	0.330
SERPINE1	0.7989	0.7406–0.8571	141	54	13	70	0.668	0.806	0.916	0.435
SDC1	0.8161	0.7602–0.8719	145	58	9	66	0.687	0.866	0.942	0.468
10-Biomarker combination	0.8925	0.8507–0.9343	179	54	13	32	0.848	0.806	0.932	0.628

AUC area under the curve, CI confidence interval, PPV positive predictive value, NPV negative predictive value

ISSN: 1479-5876